Jan 17 (Reuters) - Theratechnologies Inc TH.TO
* Theratechnologies-Abstract submitted by its partner, Taimed Biologics, for 24-week study of Ibalizumab phase III study has been selected for late breaker presentation Source text for Eikon: Further company coverage: TH.TO